Moreover, it has been suggested that HER2 overexpression or amplification in breast cancer predicts greater sensitivity to anthracycline-containing chemotherapy (Gennari et al, 2008) and resistance to the CMF regimen (Gusterson et al, 1992). This evidence concerns the gene ERBB2 and breast cancer.